Literature DB >> 29937315

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.

Allison A Gockley1, David L Kolin2, Christopher S Awtrey3, Neal I Lindeman4, Ursula A Matulonis5, Panagiotis A Konstantinopoulos6.   

Abstract

A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly (ADP ribose) polymerase (PARP) inhibitor, olaparib. Molecular and treatment factors are discussed.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29937315     DOI： 10.1016/j.ygyno.2018.05.028

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  4 in total

Review 1.  Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.

Authors:  Qiao Wang; Hongling Peng; Xiaorong Qi; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-07-29

2.  Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report.

Authors:  Kayo Inoue; Hiroshi Tsubamoto; Tomoko Ueda; Chihiro Tajima; Nami Nakagomi
Journal:  Gynecol Oncol Rep       Date:  2020-04-05

3.  Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.

Authors:  Jinhui Liu; Rui Geng; Sheng Yang; Fang Shao; Zihang Zhong; Min Yang; Senmiao Ni; Lixin Cai; Jianling Bai
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

4.  Application of Jianpi Xiaoai Recipe Combined with Cisplatin and Adriamycin in the Treatment of Endometrial Cancer and Its Effect on Disease Control Rate.

Authors:  Li Ding; Hongyu Li; Yuping Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-28       Impact factor: 2.629
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.